April 23, 2024 1:19 pm
FDA approves AI stethoscope technology capable of identifying heart failure

More than 11 million people worldwide are living with heart failure and reduced ejection fraction, as reported in a 2020 study by the American Medical Association. In the United States, over 6 million Americans are affected by heart failure. To help detect heart failure in just seconds, a new artificial intelligence (AI) technology developed by Mayo Clinic and Eko Health has recently received FDA-clearance.

The traditional stethoscope, which has been used since 1816, has been upgraded with an AI makeover. Doctors use the stethoscope to listen to a patient’s heart and lungs to make diagnostic assessments. However, further tests such as CT or MRI scans may be necessary for a definitive diagnosis. An electrocardiogram (ECG) is also used to measure the heart’s electrical activity.

Connor Landgraf, CEO of Eko Health, is passionate about using AI to enhance medical care. His family’s history of pulmonary disease inspired him to explore better technologies for identifying early signs of illness. The AI program developed by Mayo Clinic and Eko Health was trained on recordings from over 100,000 patients to interpret heart activity. This allows it to quickly assess a person’s heart strength and detect early signs of heart failure with low ejection fraction in just seconds.

Dr. Paul Friedman, a cardiologist at Mayo Clinic, emphasizes the importance of early detection for heart failure. If left untreated, heart failure can lead to serious complications such as stroke or kidney damage. The AI-enhanced stethoscope is now available for $429 with a monthly subscription and is a breakthrough technology that can help identify heart issues that might otherwise go undetected.

In conclusion, the new AI-enhanced stethoscope developed by Mayo Clinic and Eko Health provides doctors with an efficient tool for diagnosing heart failure in just seconds. With more than 6 million Americans affected by heart failure in the US alone and over 11 million worldwide living with reduced ejection fraction, early detection is crucial for improving patient outcomes and preventing serious complications from developing.

Leave a Reply